WO2001013121A1 - Methods for identification of compounds stimulating insulin secretion - Google Patents

Methods for identification of compounds stimulating insulin secretion Download PDF

Info

Publication number
WO2001013121A1
WO2001013121A1 PCT/SE2000/001563 SE0001563W WO0113121A1 WO 2001013121 A1 WO2001013121 A1 WO 2001013121A1 SE 0001563 W SE0001563 W SE 0001563W WO 0113121 A1 WO0113121 A1 WO 0113121A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
tubulin
binding
insulin secretion
sulfonylurea
Prior art date
Application number
PCT/SE2000/001563
Other languages
French (fr)
Inventor
Per-Olof Berggren
Thomas LUNDBÄCK
Alejandro Bertorello
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Priority to JP2001517172A priority Critical patent/JP2003507365A/en
Priority to CA002380983A priority patent/CA2380983A1/en
Priority to EP00953612A priority patent/EP1200835A1/en
Priority to NZ516788A priority patent/NZ516788A/en
Priority to AU66032/00A priority patent/AU6603200A/en
Publication of WO2001013121A1 publication Critical patent/WO2001013121A1/en
Priority to NO20020576A priority patent/NO20020576D0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • ⁇ -tubulin as well as a new polypeptide present in pancreatic ⁇ - cells, have been identified as molecular targets for sulfonylurea compounds. These findings enable for the identification of new insulin secretagogues.
  • the invention thus relates to the use of sulfonylurea compounds, such as e.g. glibenclamide, in methods for identification of compounds binding the new polypeptide or tubulin, or stimulating tubulin polymerization and/or turnover, said compounds thereby stimulating insulin secretion.
  • Diabetes mellitus is a chronic disease affecting approximately 3-5% of the Swedish population and it is associated with a variety of severe late complications leading to enhanced morbidity and mortality. Thus, this disease markedly compromises the health and life quality of affected individuals and consumes a substantial amount of the health care budget.
  • Hyperglycemia is a major risk factor for the development of the specific diabetes-associated complications and probably also for the increased risk of cardiovascular disease. Early intervention, which requires diagnosis in the prediabetic state, is expected to contribute to a reduction of the diabetic complications. Hence, there is an urgent need for precise methods in the early detection of individuals at risk for the development of diabetes. Furthermore, there is a need for the design of new concepts and drugs for prevention and treatment of diabetes. A better understanding of the biochemical, cellular, genetic and molecular basis for the development of hyperglycemia and the effect of hyperglycemia on both release and action of insulin will pave the way for new drugs and future development of gene therapy in the treatment of diabetes. A defective insulin release is a characteristic of non-insulin dependent diabetes mellitus (NIDDM) and to some extent also to the early phase of insulin-dependent diabetes mellitus (IDDM).
  • NIDDM non-insulin dependent diabetes mellitus
  • K ATP channels ATP-regulated K + -channels
  • the K ATP channel is composed of at least two components: a sulfonylurea receptor (SUR) and an inward rectifier potassium channel protein (Aguilar-Bryan, L. et al. (1995) Science 268: 423-426).
  • Sulfonylureas (SU) to SURl , the ⁇ -cell variant of SUR, results in the closure of the K ATP channels and thereby insulin release in the ⁇ -cell.
  • Sulfonylurea compounds such as glibenclamide (glyburide; 5-Chloro-N-[2-[4-[[[(cyclohexylamino) carbonyl] amino] sulfonyl]phenyl] ethyl]- 2-methoxybenzamide, CAS: [10238-21-8]
  • glibenclamide glutamino-N-[2-[4-[[[[(cyclohexylamino) carbonyl] amino] sulfonyl]phenyl] ethyl]- 2-methoxybenzamide, CAS: [10238-21-8]
  • NIDDM for a review, see Luzi, L. & Pozza, G. (1997) Acta Diabetol. 34, 239-244)
  • Sulfonylurea compounds are capable of promoting insulin secretion even in the absence of changes in membrane potential and intracellular calcium. It has been shown that sulfonylurea compounds directly promote exocytosis of insulin (Eliasson L. et al. (1996) Science 271 : 813-815; Flatt et al. (1994) Diabete et Metabolisme 20: 157-162). This effect is dependent on protein kinase C and is observed at therapeutic concentrations of sulfonylureas, which suggests that it contributes to their hypoglycemic action in diabetics.
  • microtubule stabilizers e.g. D 2 O and ethanol
  • destabilizers e.g. colchicine and vincristine
  • Binding of [ 125 I] glibenclamide to pancreatic ⁇ -cells was examined in intact ⁇ -cells and subcellular fractions (cytosol and membranes) derived therefrom. Cross-linking (UN) did not affect the magnitude of the binding.
  • C The cytosolic fraction was further analyzed by 2-dimensional electrophoresis and autoradiography.
  • Glibenclamide accelerates microtubule growth
  • (a): Experimental data showing the increase in optical density at 340 nm, resulting from tubulin polymerization in vitro, as a function of time. Microtubule growth was induced by increasing the temperature from 15°C (at t 0) to 35°C.
  • the concentration of bovine brain tubulin was 2.9 mg/ml and the buffer solution contain 80 mM Pipes, 1 mM MgCl 2 , 1 mM EGTA, 1 mM GTP, 2.1% DMSO and 10% glycerol at pH 6.9.
  • the black symbols indicate the presence of 0.17 mM glibenclamide whereas the gray symbols represent the controls in its absence.
  • ⁇ -tubulin as well as a 65 kDa polypeptide present in pancreatic ⁇ -cells, have surprisingly been identified as molecular targets for sulfonylurea compounds.
  • These findings enable for the identification of new insulin secretagogues, which can be sulfonylureas or other compounds acting on these intracellular sulfonylurea targets.
  • the methods according to the invention address a mechanism for insulin secretion, which is independent of the sulfonylurea receptor/K + -ATP complex.
  • this invention provides the use of tubulin and/or the -65 kDa polypeptide, identified according to the Examples below, as targets in the identification of active agents useful for stimulating insulin secretion and thereby useful in the treatment of hyperglycemia and diabetes, in particular NIDDM.
  • the said active agent could e.g. be a sulfonylurea derivative, or any other compound acting on intracellular targets indicated below.
  • the said active agent could e.g. be a derivative of a "second generation" sulfonylurea, such as glibenclamide (glyburide) or glipizide.
  • the said active agent should be stimulating insulin secretion independently of the plasma membrane sulfonylurea receptor activity in the presence, but not in the absence, of stimulatory glucose concentrations.
  • stimulatory glucose concentrations means a postprandial blood glucose level, such as blood glucose higher than approximately 8 mM.
  • This invention further provides a method for the identification of a compound capable of binding to the ⁇ 65 kDa polypeptide as defined in the Examples below, said method comprising the steps (a) contacting the said -65 kDa polypeptide with a test compound; and (b) determining the binding of the said test compound to the said -65 kDa polypeptide.
  • Such a method could include the additional steps of contacting the said -65 kDa polypeptide with a reference compound binding to the said polypeptide; and determining the binding of the said test compound, relative to that of the said reference compound, to the said -65 kDa polypeptide.
  • the reference compound could be any compound known to bind the 65 kDa polypeptide. It is shown in Example 1, below, that the sulfonylurea glibenclamide (glyburide) is associated with the 65 kDa polypeptide and thus glibenclamide is suitable as a reference compound. It is anticipated that additional suitable reference substances are other sulfonylurea compounds known to stimulate insulin secretion, such as tolbutamide, chlorpropamide, acetohexamide, tolazamide, glimepiride, or a "second generation" sulfonylurea (like glibenclamide) such as glipizide.
  • Sulfonylurea compounds that could be used include those having a generic formula disclosed in e.g. United States patent Nos. 3,454,635; 3,669,966; or 4,379,785. However, by using the methods according to the invention, the skilled person will be able to identify additional sulfonylurea compounds, sulfonylurea derivatives or other substances, and subsequently use them as reference substances.
  • the invention provides a method for the identification of a compound capable of binding to tubulin, comprising the steps (a) contacting tubulin with (i) a test compound and (ii) a reference compound which is a sulfonylurea compound, or a derivative thereof, binding to tubulin; and (b) determining the binding of the said test compound, relative to that of the said reference compound, to tubulin.
  • the said sulfonylurea compound could be any of the sulfonylurea compounds discussed above.
  • the skilled person will be able to identify additional sulfonylurea compounds, sulfonylurea derivatives or other substances, and subsequently use them as reference substances.
  • binding, in particular a high degree of binding, of the said test compound to the -65 kDa polypeptide or to tubulin, respectively, is indicative of a compound capable of stimulating insulin secretion.
  • An alternative method for the identification of a compound capable of binding to tubulin could comprise the steps (a) contacting tubulin with (i) a test compound and (ii) a reference compound which is a sulfonylurea compound, or a derivative thereof, binding to tubulin; and (b) determining the stimulating effect of the said test compound, relative to that of the said reference compound, to polymerization or turnover of tubulin.
  • a stimulating effect on polymerization or turnover of tubulin is indicative of a compound capable of stimulating insulin secretion.
  • the said tubulin could be from any source, but is preferably isolated from humans and in particular human ⁇ -cells.
  • Both ⁇ -tubulin and ⁇ - tubulin consist of various isotypes and there are differences in their tissue distributions (Roach, M.C. et al. (1998) Cell Motility and the Cytoskeleton 39, 273-285; Luduena, R.F. (1993) Mol. Biol. Cell 4:445-457; Luduena, R.F. (1998) Int. Rev. Cytology 178: 207-275).
  • the differences among the ⁇ isotypes are known to be conserved in evolution. Since isotypes may differ in their functional assignments or roles in cells, it may be particularly advantageous to use tubulin derived from ⁇ -cells when screening for compounds stimulating insulin secretion.
  • the reference compound could be labeled, e.g. radiolabeled or fluorescence labeled, and binding of the said reference compound to tubulin or the -65 kDa polypeptide could be determined by methods such autoradiography or fluorescence spectroscopy (e.g. fluorescence polarization, fluorescence correlation spectroscopy, or confocal microscopy (see e.g. Example 1, below)).
  • fluorescence spectroscopy e.g. fluorescence polarization, fluorescence correlation spectroscopy, or confocal microscopy (see e.g. Example 1, below).
  • fluorescence spectroscopy see Joseph R. Lakowicz: Principles of fluorescence spectroscopy, Second edition, Kluwer Academic/Plenum Publishers, New York, 1999, ISBN 0-306-46093-9.
  • tubulin to form microtubules can be followed by a number of methods known in the art, e.g. by observing the increase in optical density of a tubulin solution as described in Example 2, below.
  • Methods known in the art e.g. by observing the increase in optical density of a tubulin solution as described in Example 2, below.
  • fluorescence labeled tubulin proteins which upon polymerization end up in close proximity to each other (e.g. quenching or fluorescence resonance energy transfer phenomena).
  • fluorescence spectroscopy methods are described in the art e.g. by Lakowicz, supra.
  • Microtubule treadmilling (for a review, see Margolis, R. L. & Wilson, L. (1998) Bioessays 20, 830-836) represents the simultaneous addition of a tubulin heterodimer at one microtubule end and the removal at the other. This phenomenon occurs in living cells and appears to be essential to the biological function of the microtubules (Rodionov, V. I. et al. (1997) Science 275, 215-218).
  • the incorporation of fluorescence labeled tubulin molecules in pre-existing microtubules can thus be utilized in cell-based assays, or alternatively in vitro by fluorescence spectroscopy measurements, e.g. fluorescence anisotropy or correlation spectroscopy, for screening of compounds that via the microtubule network affect secretion of insulin.
  • this invention relates to a method for the treatment of diabetes and/or hyperglycemia comprising administering to a patient in need thereof an effective amount of a compound identified by any one of the methods according to the invention.
  • effective amount means a dosage sufficient to provide treatment for the disease state being treated.
  • the typical daily dose of the active compound varies within a wide range and will depend on various factors such as for example the individual requirement of each patient and the route of administration. In general, daily dosages could be in the range of 0.1 to 1000 mg, such as 1 to 50 mg or 2.5 to 20 mg. It is anticipated that the agents identified by the methods according to the invention could have reduced side effects compared to sulfonylurea compounds known in the art. For a review of the adverse effects and precautions of sulfonylurea drugs, see Paice, BJ et al. (1985) Adverse Drug React. Acute Poisoning Rev. 4: 23-36.
  • this invention provides an isolated mammalian polypeptide characterized by binding to glibenclamide and an apparent molecular mass of approximately 65 kDa.
  • this polypeptide can be identified when the cytosolic fraction of pancreatic ⁇ -cells from ob/ob mice is analyzed by SDS-PAGE.
  • the invention includes the isolated glibenclamide-binding -65 kDa polypeptide from any mammalian source.
  • EXAMPLE 1 Sulfonylureas associate with 47 kDa and 65 kDa proteins in ⁇ -cell cytosolic fractions from ob/ob mice.
  • Ob/ob mice were obtained from a locally bread colony at the animal facility within the Karolinska Institute, Sweden. The ob/ob mice were starved overnight. The animals were decapitated, the pancreas was excised from the abdominal cavity and pancreatic ⁇ -cells were isolated after collagenase digestion as previously described (Lernmark, A, (1974) Diabetologica 10, 431-438; Nilsson, T. et al. (1987) Biochem. J. 248, 329-336).
  • the cells were kept overnight in RPMI 1640 medium supplemented with 11 mM glucose, 10% FCS, 100 ⁇ g/ml streptomycin and 100 IU/ml penicillin at 37°C in a humidified atmosphere of 5% CO 2 in air.
  • Binding of [ 125 I] glibenclamide was performed in intact ⁇ -cells and in subcellular fraction derived therefrom.
  • Isolated pancreatic islets from ob/ob mice 250-300 were homogenized in 300 ⁇ l buffer containing (in mM): HEPES 20, MgCl 2 1, EGTA 1, EDTA 1, PMSF 1, protease inhibitors (leupeptin, aprotinin, pepstatin, antipain) 0.5 ⁇ g/ml in Eppendorf tubes using a motor pestle homogenizer.
  • the homogenized material was centrifuged (800 x g for 10 min) and the resultant pellet was resuspended again in 200 ⁇ l of homogenization buffer and centrifuged as above. Supernatants from both centrifugations were pooled for high-speed separation (100,000 x g for 30 min) of membranes and cytosol. Aliquots were incubated in the presence of 5 nM [ 125 I]glibenclamide (2 ⁇ Ci/sample) with or without xlOO excess of cold glibenclamide. Samples were irradiated for 20 min by 312 nM UV light at room temperature. The reaction was terminated by placing the samples on ice and subjected to SDS-PAGE using standard procedures.
  • Two-dimensional electrophoresis was performed in samples (200 mg protein) to which the following was added: urea powder (final concentration 6 M), isoelectric focusing sample concentrate (33.3% of 3.5-10 ampholine, 16.6% of 2-mercaptoethanol, 33.3% Triton-X 100, 16.6% of 10% SDS). Samples were incubated for 30 min at room temperature and loaded on the gel. After isoelectric focusing (900 V, 14 h), the gels were taken out of the tubes, soaked for 30 min at room temperature in Laemmli buffer, and loaded on a 6.6-13.6% gradient gel.
  • the 145 kDa protein was identified as the regulatory component (SUR-1) of the K + -ATP channel.
  • SUR-1 regulatory component
  • the identities of the cytosolic proteins were investigated.
  • the cytosolic material was separated using 2-dimensional gel electrophoresis (Fig. 1 c), and the proteins were excised for in-gel digestion and MALDI spectrum analysis.
  • the analysis of the 47 kDa protein revealed that it is ⁇ -tubulin.
  • Peptides found in the MALDI spectrum (19 of the peptide masses) were applied to the MS-Fit peptide fingerprinting tool. Peptide mass fingerprinting was performed using the MS-Fit algorithm developed at the UCSF Mass Spectrometry Facility and available via http://prospector.ucsf.edu.
  • the best hit was mouse tubulin ⁇ -5 chain (16 matches out of 19), whereas in the NCBI non-redundant database, the best hit was mouse tubulin ⁇ -3 chain (17 matches out of 19).
  • the database search for the -65 kDa protein did not match any known protein sequence.
  • sulfonylureas binding to ⁇ -tubulin was performed using confocal microscopy in primary cultures of ⁇ -cells obtained from ob/ob mice. Isolated ⁇ -cells in culture were incubated in the presence or absence of different agonists for 3 min at 23°C. The incubation time was terminated by fixation of the cells with 4% formaldehyde in PBS for 10 min at room temperature. After rinsing twice with PBS, cells were incubated in acetone at -20°C for 5 min and then quenched with PBS containing 1% BSA for 30 min.
  • BODIPY® FL glibenclamide was purchased from Molecular Probes, Inc., Catalog Number B-7439; http://www.probes.com). The green-fluorescent BODIPY® FL fluorophore has excitation/emission maxima -503/512 run. Staining with BODIPY® FL glibenclamide, primary anti ⁇ -tubulin antibody (Amersham, UK) and secondary Texas Red®-conjugated antibody (Molecular Probes Inc.) was performed at room temperature for 1 h.
  • the coverslips were mounted (SlowFade light, Molecular Probes, Eugene, OR) and examined using a confocal laser scanning microscope (Leica TCS NT, Leica Lasertechnik GmbH, Heidelberg, Germany). Excitation wavelengths 488 nm and 568 nm were used.
  • the confocal microscope was equipped with an Ar/Kr laser, a double dicroic mirror for rhodamine/fluorescein and a 63x lens (Leica PL APO 63x/l .32-0.6 oil). Analysis of the data was performed with the IMARIS and COLOCALISATION softwares (Bitplane, Zurich, Switzerland). Co-localization analysis of the data indicated an interaction between glibenclamide and ⁇ -tubulin. Interestingly this interaction is mainly localized to the interior of the ⁇ -cell and excluded the plasma membrane.
  • tubulin polymerization is commonly initiated in vitro either by addition of a crucial buffer component such as GTP or Mg 2+ (Weisenberg, R.C. (1972) Science 177, 1104-1105) or, alternatively, by an increase in temperature.
  • a crucial buffer component such as GTP or Mg 2+ (Weisenberg, R.C. (1972) Science 177, 1104-1105) or, alternatively, by an increase in temperature.
  • Tubulin from bovine brain was purchased from Cytoskeleton Inc. in aliquots of 1 mg lyophilized protein. Glibenclamide was purchased from Sigma and stocks containing 4 mg/ml were prepared daily in dimethylsulfoxide (DMSO). Immediately prior to the microtubule growth experiments each milligram of tubulin was resuspended in 350 ⁇ l ice- cold buffer solution (80 mM PIPES, 1 mM MgCl 2 , 1 mM EGTA and 10% glycerol at pH 6.9) followed by addition of 1 mM ice-cold GTP (Sigma). The samples were mixed and kept on ice for 5 minutes.
  • DMSO dimethylsulfoxide
  • EXAMPLE 3 Taxol inhibits, and nocodazole stimulates, sulfonylurea effects on insulin secretion
  • Taxol a promotor of microtubule polymerization, and nocodazole, which induces microtubule depolymerization, have earlier been shown to inhibit glucose-stimulated insulin secretion from isolated rat islets of Langerhans (Howell, S.L. et al. (1982)
  • Taxol and nodocazole were used to study the functional importance of ⁇ -cell microtubules during the process of insulin secretion.
  • the basal medium used for isolation and for conducting the experiments was a buffer containing 125 mM NaCl; 5.9 mM KC1; 1.3 mM CaCl 2 ; 1.2 mM MgCl 2 ; and 25 mM HEPES (pH 7.4).
  • BSA was added to the medium at the concentration of 1 mg/ml.
  • the dynamics of insulin release were studied by perifusing ⁇ -cell aggregates mixed with Bio- Gel P4 polyacrylamide beads (BioRad, Richmond, CA), in a 0.5 ml column at 37°C (Kanatsuna, T. et al. (1981) Diabetes 30, 231-234). The flow rate was 0.2 ml/min. Two- min fractions were collected and insulin content was analyzed by radioimmunoassay.
  • samples are separated by HPLC and fractions containing the radiolabeled protein separated on SDS-PAGE, and subject to gel staining and autoradiography.
  • the radioactive band will be excised from the gel and sequenced.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

According to the invention β-tubulin, as well as a 65 kDa polypeptide present in pancreatic β-cells, have been identified as molecular targets for sulfonylurea compounds. These findings enable for the identification of new insulin secretagogues. The invention thus relates to the use of sulfonylurea compounds, such as e.g. glibenclamide, in methods for identification of compounds binding the 65 kDa polypeptide or tubulin, or stimulating tubulin polymerization and/or turnover, said compounds thereby stimulating insulin secretion.

Description

- 1 -
METHODS FOR IDENTIFICATION OF COMPOUNDS STIMULATING INSULIN SECRETION
TECHNICAL FIELD
According to the invention β-tubulin, as well as a new polypeptide present in pancreatic β- cells, have been identified as molecular targets for sulfonylurea compounds. These findings enable for the identification of new insulin secretagogues. The invention thus relates to the use of sulfonylurea compounds, such as e.g. glibenclamide, in methods for identification of compounds binding the new polypeptide or tubulin, or stimulating tubulin polymerization and/or turnover, said compounds thereby stimulating insulin secretion.
BACKGROUND ART
Diabetes mellitus is a chronic disease affecting approximately 3-5% of the Swedish population and it is associated with a variety of severe late complications leading to enhanced morbidity and mortality. Thus, this disease markedly compromises the health and life quality of affected individuals and consumes a substantial amount of the health care budget.
Hyperglycemia is a major risk factor for the development of the specific diabetes-associated complications and probably also for the increased risk of cardiovascular disease. Early intervention, which requires diagnosis in the prediabetic state, is expected to contribute to a reduction of the diabetic complications. Hence, there is an urgent need for precise methods in the early detection of individuals at risk for the development of diabetes. Furthermore, there is a need for the design of new concepts and drugs for prevention and treatment of diabetes. A better understanding of the biochemical, cellular, genetic and molecular basis for the development of hyperglycemia and the effect of hyperglycemia on both release and action of insulin will pave the way for new drugs and future development of gene therapy in the treatment of diabetes. A defective insulin release is a characteristic of non-insulin dependent diabetes mellitus (NIDDM) and to some extent also to the early phase of insulin-dependent diabetes mellitus (IDDM).
An initial step in the β-cell stimulus-secretion coupling is metabolism of glucose, resulting in the formation of ATP. ATP closes the ATP-regulated K+-channels (KATP channels), resulting in plasma membrane depolarization, opening of voltage-gated L-type Ca +-channels and increase in cytoplasmic free Ca2+ concentration, [Ca2+]i. The KATP channel is composed of at least two components: a sulfonylurea receptor (SUR) and an inward rectifier potassium channel protein (Aguilar-Bryan, L. et al. (1995) Science 268: 423-426). The binding of sulfonylureas (SU) to SURl , the β-cell variant of SUR, results in the closure of the KATP channels and thereby insulin release in the β-cell. Sulfonylurea compounds, such as glibenclamide (glyburide; 5-Chloro-N-[2-[4-[[[(cyclohexylamino) carbonyl] amino] sulfonyl]phenyl] ethyl]- 2-methoxybenzamide, CAS: [10238-21-8]) have been used in the treatment of NIDDM (for a review, see Luzi, L. & Pozza, G. (1997) Acta Diabetol. 34, 239-244).
Sulfonylurea compounds are capable of promoting insulin secretion even in the absence of changes in membrane potential and intracellular calcium. It has been shown that sulfonylurea compounds directly promote exocytosis of insulin (Eliasson L. et al. (1996) Science 271 : 813-815; Flatt et al. (1994) Diabete et Metabolisme 20: 157-162). This effect is dependent on protein kinase C and is observed at therapeutic concentrations of sulfonylureas, which suggests that it contributes to their hypoglycemic action in diabetics. It has been suggested that 80-90% of the SU binding proteins is localized to intracellular membranes, including those of the secretory granules (Ozanne S.E. et al. (1995) Diabetologia 38, 277-282). The molecular mechanism underlying this direct effect of sulfonylureas on insulin exocytosis is not known.
Consequently, there is a need for identification of new intracellular targets that could explain the effect of sulfonylureas on insulin exocytosis via a pathway independent of the sulfonylurea receptor (SUR-1) and the ATP-regulated K+-channel . Such targets could be utilized in methods for the identification of new compounds stimulating insulin secretion. The involvement of the microtubular network in glucose-induced insulin secretion has been suggested (Lacy, P. E. et al. (1968) Nature 219, 1177-1179). The hypothesis was based on the decreased insulin secretion observed in the presence of drugs that inhibit polymerization of the tubulin heterodimer to form microtubules. Subsequent studies revealed that the reduced secretion was observed both in the presence of microtubule stabilizers (e.g. D2O and ethanol) and destabilizers (e.g. colchicine and vincristine) (Malaisse, W. J. et al. (1970) Diabetologia 6, 683; Malaisse, W. J. et al. (1971) Diabetes 20, 257-265). It was also shown that the observed effect did not result from an altered insulin production or calcium uptake, demonstrating that it was the transport and/or secretion of insulin containing granules that was not functional. Following these results a model of insulin secretion was presented in which the second sustained phase of secretion depends on the directional transport of insulin granules along the microtubular network (Malaisse, W. J. et al. (1974) Eur. J. Clin. Invest. 4, 313-318).
A number of reports have since confirmed the importance of the microtubular system in insulin secretion (for a review, see Howell, S. L. & Tyhurst, M. (1986) Diabetes/Metabolism Reviews, 2, 107-123). These studies revealed that the integrity and/or the dynamic equilibrium (treadmilling as well as phases of microtubule growth and shortening) of the microtubules are essential for glucose-stimulated insulin secretion. Of interest from a pharmaceutical viewpoint is to identify agents that act on the microtubule network to specifically enhance insulin secretion. This task is not trivial as the microtubular network is generally involved in secretory processes in several endocrine organs and glands (see e.g. Poisner, A. M. & Bernstein, J. (1971) J. Pharmacol. Exp. Ther. 177, 102-108; Neve, P. et al. (1970) Exp. Cell Res. 63, 457-460; Williams, J. A. & Wolff, J. (1970) Proc. Natl. Acad. Sci. U.S.A. 67, 1901-1908; Kraicer, J. & Milligan, J. V. (1971) Endocrinology 89, 408-412) and hence not expected to be a suitable target for a specific insulin secretagogue. BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1
Binding of [125I] glibenclamide to pancreatic β-cells. (A) Binding of glibenclamide was examined in intact β-cells and subcellular fractions (cytosol and membranes) derived therefrom. Cross-linking (UN) did not affect the magnitude of the binding. (B) The cross- linked samples were further analyzed by SDS-PAGE and autoradiography (C, cytosol and M, membranes). These fractions were washed extensively, centrifuged and the supernatant (S) and pellets (P) further analyzed by SDS-PAGE and autoradiography. (C) The cytosolic fraction was further analyzed by 2-dimensional electrophoresis and autoradiography.
Fig. 2
Glibenclamide accelerates microtubule growth, (a): Experimental data showing the increase in optical density at 340 nm, resulting from tubulin polymerization in vitro, as a function of time. Microtubule growth was induced by increasing the temperature from 15°C (at t=0) to 35°C. The concentration of bovine brain tubulin was 2.9 mg/ml and the buffer solution contain 80 mM Pipes, 1 mM MgCl2, 1 mM EGTA, 1 mM GTP, 2.1% DMSO and 10% glycerol at pH 6.9. The black symbols indicate the presence of 0.17 mM glibenclamide whereas the gray symbols represent the controls in its absence. The polymerization was followed simultaneously for one pair at the time, with each pair being a glibenclamide sample and a control, to ensure comparisons are made on identical protein samples. The data presented is representative of four experiments, (b): The rate of tubulin polymerization as measured by the change in OD with time (dOD/dt) as a function of time. The experimental conditions were the same as in (a). Black lines indicate the presence of glibenclamide and gray lines its absence.
Fig. 3
Staining of microtubules with an antibody against tubulin in β-cells pretreated with vehicle, nocodazole or taxol (a). Data are representative of three determinations. Effect of nocodazole (b) and taxol (c) on the dynamics of insulin release from column perifused β- cells. Cells were incubated with 5 μM nocodazole for 30 min or 25 μM taxol for 15 min prior to starting perifusion of the cells. Taxol was present during the whole experiment. The control cells were incubated with their respective vehicle solutions. Protocols were initiated at the times indicated in the figure with either 1 μM glibenclamide or 15 mM glucose. The data represents the mean ± SEM of four experiments.
DISCLOSURE OF THE INVENTION
According to the invention β-tubulin, as well as a 65 kDa polypeptide present in pancreatic β-cells, have surprisingly been identified as molecular targets for sulfonylurea compounds. These findings enable for the identification of new insulin secretagogues, which can be sulfonylureas or other compounds acting on these intracellular sulfonylurea targets. The methods according to the invention address a mechanism for insulin secretion, which is independent of the sulfonylurea receptor/K+-ATP complex.
To the inventors' knowledge, there are no indications in the prior art that sulfonylureas interact with tubulin or with the said -65 kDa polypeptide, which polypeptide as such is an aspect of the invention. Further, it has not been previously shown that compounds which stimulate insulin secretion also have a stimulating effect on tubulin polymerization.
Consequently, in one aspect this invention provides the use of tubulin and/or the -65 kDa polypeptide, identified according to the Examples below, as targets in the identification of active agents useful for stimulating insulin secretion and thereby useful in the treatment of hyperglycemia and diabetes, in particular NIDDM.
The said active agent could e.g. be a sulfonylurea derivative, or any other compound acting on intracellular targets indicated below. The said active agent could e.g. be a derivative of a "second generation" sulfonylurea, such as glibenclamide (glyburide) or glipizide. In particular, the said active agent should be stimulating insulin secretion independently of the plasma membrane sulfonylurea receptor activity in the presence, but not in the absence, of stimulatory glucose concentrations. As used herein the term "stimulatory glucose concentrations" means a postprandial blood glucose level, such as blood glucose higher than approximately 8 mM.
This invention further provides a method for the identification of a compound capable of binding to the ~65 kDa polypeptide as defined in the Examples below, said method comprising the steps (a) contacting the said -65 kDa polypeptide with a test compound; and (b) determining the binding of the said test compound to the said -65 kDa polypeptide.
Such a method could include the additional steps of contacting the said -65 kDa polypeptide with a reference compound binding to the said polypeptide; and determining the binding of the said test compound, relative to that of the said reference compound, to the said -65 kDa polypeptide.
When the method according to the invention involves the use of a reference compound, the reference compound could be any compound known to bind the 65 kDa polypeptide. It is shown in Example 1, below, that the sulfonylurea glibenclamide (glyburide) is associated with the 65 kDa polypeptide and thus glibenclamide is suitable as a reference compound. It is anticipated that additional suitable reference substances are other sulfonylurea compounds known to stimulate insulin secretion, such as tolbutamide, chlorpropamide, acetohexamide, tolazamide, glimepiride, or a "second generation" sulfonylurea (like glibenclamide) such as glipizide. Sulfonylurea compounds that could be used include those having a generic formula disclosed in e.g. United States patent Nos. 3,454,635; 3,669,966; or 4,379,785. However, by using the methods according to the invention, the skilled person will be able to identify additional sulfonylurea compounds, sulfonylurea derivatives or other substances, and subsequently use them as reference substances.
In addition, the invention provides a method for the identification of a compound capable of binding to tubulin, comprising the steps (a) contacting tubulin with (i) a test compound and (ii) a reference compound which is a sulfonylurea compound, or a derivative thereof, binding to tubulin; and (b) determining the binding of the said test compound, relative to that of the said reference compound, to tubulin. The said sulfonylurea compound could be any of the sulfonylurea compounds discussed above. As mentioned above, by using the methods according to the invention, the skilled person will be able to identify additional sulfonylurea compounds, sulfonylurea derivatives or other substances, and subsequently use them as reference substances.
In methods described above, binding, in particular a high degree of binding, of the said test compound to the -65 kDa polypeptide or to tubulin, respectively, is indicative of a compound capable of stimulating insulin secretion.
An alternative method for the identification of a compound capable of binding to tubulin, could comprise the steps (a) contacting tubulin with (i) a test compound and (ii) a reference compound which is a sulfonylurea compound, or a derivative thereof, binding to tubulin; and (b) determining the stimulating effect of the said test compound, relative to that of the said reference compound, to polymerization or turnover of tubulin. In such a method, a stimulating effect on polymerization or turnover of tubulin is indicative of a compound capable of stimulating insulin secretion.
In the methods described above, the said tubulin could be from any source, but is preferably isolated from humans and in particular human β-cells. Both α-tubulin and β- tubulin consist of various isotypes and there are differences in their tissue distributions (Roach, M.C. et al. (1998) Cell Motility and the Cytoskeleton 39, 273-285; Luduena, R.F. (1993) Mol. Biol. Cell 4:445-457; Luduena, R.F. (1998) Int. Rev. Cytology 178: 207-275). The differences among the β isotypes are known to be conserved in evolution. Since isotypes may differ in their functional assignments or roles in cells, it may be particularly advantageous to use tubulin derived from β-cells when screening for compounds stimulating insulin secretion.
The reference compound could be labeled, e.g. radiolabeled or fluorescence labeled, and binding of the said reference compound to tubulin or the -65 kDa polypeptide could be determined by methods such autoradiography or fluorescence spectroscopy (e.g. fluorescence polarization, fluorescence correlation spectroscopy, or confocal microscopy (see e.g. Example 1, below)). For a general review on fluorescence spectroscopy methods, see Joseph R. Lakowicz: Principles of fluorescence spectroscopy, Second edition, Kluwer Academic/Plenum Publishers, New York, 1999, ISBN 0-306-46093-9.
The polymerization of tubulin to form microtubules can be followed by a number of methods known in the art, e.g. by observing the increase in optical density of a tubulin solution as described in Example 2, below. There are numerous publications available in which this technique has been used (see e.g. Microtubule Proteins, Editor: Avila, J., 1990, CRC Press). Tubulin polymerization can also be followed using fluorescence labeled tubulin proteins, which upon polymerization end up in close proximity to each other (e.g. quenching or fluorescence resonance energy transfer phenomena). As mentioned above, fluorescence spectroscopy methods are described in the art e.g. by Lakowicz, supra.
Microtubule treadmilling (for a review, see Margolis, R. L. & Wilson, L. (1998) Bioessays 20, 830-836) represents the simultaneous addition of a tubulin heterodimer at one microtubule end and the removal at the other. This phenomenon occurs in living cells and appears to be essential to the biological function of the microtubules (Rodionov, V. I. et al. (1997) Science 275, 215-218). The incorporation of fluorescence labeled tubulin molecules in pre-existing microtubules can thus be utilized in cell-based assays, or alternatively in vitro by fluorescence spectroscopy measurements, e.g. fluorescence anisotropy or correlation spectroscopy, for screening of compounds that via the microtubule network affect secretion of insulin.
In a further aspect, this invention relates to a method for the treatment of diabetes and/or hyperglycemia comprising administering to a patient in need thereof an effective amount of a compound identified by any one of the methods according to the invention. The term "effective amount" means a dosage sufficient to provide treatment for the disease state being treated. The typical daily dose of the active compound varies within a wide range and will depend on various factors such as for example the individual requirement of each patient and the route of administration. In general, daily dosages could be in the range of 0.1 to 1000 mg, such as 1 to 50 mg or 2.5 to 20 mg. It is anticipated that the agents identified by the methods according to the invention could have reduced side effects compared to sulfonylurea compounds known in the art. For a review of the adverse effects and precautions of sulfonylurea drugs, see Paice, BJ et al. (1985) Adverse Drug React. Acute Poisoning Rev. 4: 23-36.
In a further important aspect, this invention provides an isolated mammalian polypeptide characterized by binding to glibenclamide and an apparent molecular mass of approximately 65 kDa. In particular, this polypeptide can be identified when the cytosolic fraction of pancreatic β-cells from ob/ob mice is analyzed by SDS-PAGE. However, it will be understood that the invention includes the isolated glibenclamide-binding -65 kDa polypeptide from any mammalian source.
EXAMPLES
EXAMPLE 1 : Sulfonylureas associate with 47 kDa and 65 kDa proteins in β-cell cytosolic fractions from ob/ob mice.
(a) Binding of glibenclamide
Ob/ob mice were obtained from a locally bread colony at the animal facility within the Karolinska Institute, Stockholm, Sweden. The ob/ob mice were starved overnight. The animals were decapitated, the pancreas was excised from the abdominal cavity and pancreatic β-cells were isolated after collagenase digestion as previously described (Lernmark, A, (1974) Diabetologica 10, 431-438; Nilsson, T. et al. (1987) Biochem. J. 248, 329-336). The cells were kept overnight in RPMI 1640 medium supplemented with 11 mM glucose, 10% FCS, 100 μg/ml streptomycin and 100 IU/ml penicillin at 37°C in a humidified atmosphere of 5% CO2 in air.
Binding of [125I] glibenclamide (Amersham, UK) was performed in intact β-cells and in subcellular fraction derived therefrom. Isolated pancreatic islets from ob/ob mice (250-300) were homogenized in 300 μl buffer containing (in mM): HEPES 20, MgCl2 1, EGTA 1, EDTA 1, PMSF 1, protease inhibitors (leupeptin, aprotinin, pepstatin, antipain) 0.5 μg/ml in Eppendorf tubes using a motor pestle homogenizer. The homogenized material was centrifuged (800 x g for 10 min) and the resultant pellet was resuspended again in 200 μl of homogenization buffer and centrifuged as above. Supernatants from both centrifugations were pooled for high-speed separation (100,000 x g for 30 min) of membranes and cytosol. Aliquots were incubated in the presence of 5 nM [125I]glibenclamide (2 μCi/sample) with or without xlOO excess of cold glibenclamide. Samples were irradiated for 20 min by 312 nM UV light at room temperature. The reaction was terminated by placing the samples on ice and subjected to SDS-PAGE using standard procedures. Two-dimensional electrophoresis was performed in samples (200 mg protein) to which the following was added: urea powder (final concentration 6 M), isoelectric focusing sample concentrate (33.3% of 3.5-10 ampholine, 16.6% of 2-mercaptoethanol, 33.3% Triton-X 100, 16.6% of 10% SDS). Samples were incubated for 30 min at room temperature and loaded on the gel. After isoelectric focusing (900 V, 14 h), the gels were taken out of the tubes, soaked for 30 min at room temperature in Laemmli buffer, and loaded on a 6.6-13.6% gradient gel. Following SDS-PAGE separation, gels were stained with Coomassie Brilliant Blue R or with silver (Silver Stain Plus kit, Bio-Rad, Richmond, CA). Localization of the proteins containing the radiolabeled [125I] glibenclamide was performed by autoradiography.
Binding of [125I] glibenclamide to β-cells in suspension isolated from ob/ob mice, followed by UV cross-linking and SDS-PAGE separation was performed to determine whether this compound interacts with cellular proteins other than the SURl unit of KAτp-channels. The binding of [125I] glibenclamide to β-cells performed under steady-state conditions (30 min at 4°C) was specific (Fig. la), and sub-cellular fractionation revealed that a great proportion of such binding was localized to the plasma membrane, although -30 % of the binding remained associated with the cytosolic fraction. UV cross-linking did not significantly affect either the total binding or its distribution among the cytosolic and membrane fractions (Fig. la). This material was further analyzed by SDS-PAGE separation and autoradiography (Fig. lb). Binding of [125I] glibenclamide to β-cells was associated with a -145 kDa protein within the plasma membrane fraction. In the cytosolic fraction, glibenclamide associated with two proteins having a molecular mass of approximately 47 and 65 kDa, respectively (Fig. lb, left panel). After several washing steps the binding of [125 j] glibenclamide remained in the supernatant of the cytosolic fraction for the 65 and 47 kDa proteins (Fig. lb, middle panel) and in the pellet of the plasma membrane fraction for the 145 kDa protein (Fig. lb, right panel).
The 145 kDa protein was identified as the regulatory component (SUR-1) of the K+-ATP channel. The identities of the cytosolic proteins were investigated. The cytosolic material was separated using 2-dimensional gel electrophoresis (Fig. 1 c), and the proteins were excised for in-gel digestion and MALDI spectrum analysis. The analysis of the 47 kDa protein revealed that it is β-tubulin. Peptides found in the MALDI spectrum (19 of the peptide masses) were applied to the MS-Fit peptide fingerprinting tool. Peptide mass fingerprinting was performed using the MS-Fit algorithm developed at the UCSF Mass Spectrometry Facility and available via http://prospector.ucsf.edu. For the SwissProt database search, the best hit was mouse tubulin β-5 chain (16 matches out of 19), whereas in the NCBI non-redundant database, the best hit was mouse tubulin β-3 chain (17 matches out of 19). The database search for the -65 kDa protein did not match any known protein sequence.
(b) Confocal microscopy analysis
Further analysis of sulfonylureas binding to β-tubulin was performed using confocal microscopy in primary cultures of β-cells obtained from ob/ob mice. Isolated β-cells in culture were incubated in the presence or absence of different agonists for 3 min at 23°C. The incubation time was terminated by fixation of the cells with 4% formaldehyde in PBS for 10 min at room temperature. After rinsing twice with PBS, cells were incubated in acetone at -20°C for 5 min and then quenched with PBS containing 1% BSA for 30 min. BODIPY® FL glibenclamide was purchased from Molecular Probes, Inc., Catalog Number B-7439; http://www.probes.com). The green-fluorescent BODIPY® FL fluorophore has excitation/emission maxima -503/512 run. Staining with BODIPY® FL glibenclamide, primary anti β-tubulin antibody (Amersham, UK) and secondary Texas Red®-conjugated antibody (Molecular Probes Inc.) was performed at room temperature for 1 h. After rinsing with PBS the coverslips were mounted (SlowFade light, Molecular Probes, Eugene, OR) and examined using a confocal laser scanning microscope (Leica TCS NT, Leica Lasertechnik GmbH, Heidelberg, Germany). Excitation wavelengths 488 nm and 568 nm were used. The confocal microscope was equipped with an Ar/Kr laser, a double dicroic mirror for rhodamine/fluorescein and a 63x lens (Leica PL APO 63x/l .32-0.6 oil). Analysis of the data was performed with the IMARIS and COLOCALISATION softwares (Bitplane, Zurich, Switzerland). Co-localization analysis of the data indicated an interaction between glibenclamide and β-tubulin. Interestingly this interaction is mainly localized to the interior of the β-cell and excluded the plasma membrane.
EXAMPLE 2: Sulfonylureas affects tubulin polymerization in vitro
To determine whether binding of glibenclamide also occurs in a cell-free system, and whether it has any functional impact on the properties of tubulin, the rate of tubulin polymerization in vitro in the presence of glibenclamide was examined. Polymerization of tubulin leading to the formation of microtubules can be followed by observing the increase in optical density of a tubulin-containing solution at 340 nm. Tubulin polymerization is commonly initiated in vitro either by addition of a crucial buffer component such as GTP or Mg2+ (Weisenberg, R.C. (1972) Science 177, 1104-1105) or, alternatively, by an increase in temperature.
Tubulin from bovine brain was purchased from Cytoskeleton Inc. in aliquots of 1 mg lyophilized protein. Glibenclamide was purchased from Sigma and stocks containing 4 mg/ml were prepared daily in dimethylsulfoxide (DMSO). Immediately prior to the microtubule growth experiments each milligram of tubulin was resuspended in 350 μl ice- cold buffer solution (80 mM PIPES, 1 mM MgCl2, 1 mM EGTA and 10% glycerol at pH 6.9) followed by addition of 1 mM ice-cold GTP (Sigma). The samples were mixed and kept on ice for 5 minutes. 170 μl of this solution was subsequently transferred to each of two ice-cold Eppendorff tubes containing 3.65 μl of the glibenclamide stock in DMSO or just DMSO, respectively. Following mixing the solutions were transferred to two cuvettes equilibrated at 15°C in a CARY 4E spectrophotometer equipped with a thermostated multicell holder. The samples were left in the cuvette holder at 15°C for five minutes to allow thermal equilibrium to be reached. The experiment was then started by altering the multicell holder set temperature to 35°C and the absorbance at 340 nm was measured as a function of time. This was done simultaneously for both samples as the multicell holder changes between the two positions. Polymerization started as a result of the increased temperature and the effect of glibenclamide on the rate and extent of polymerization could be observed.
The results are shown in Fig. 2. The rate of change in absorbance was faster in the presence of 0.17 mM glibenclamide and this is the case for three independent pairs of tubulin samples. It has previously been demonstrated that changes in OD are proportional to the concentration of microtubules, regardless of the length of these polymers (Nagle, B.W. & Bryan, J. (1976) Cold Spring Harbor Symposium on Cell Proliferation 3, 1213-1232; MacNeal, R. K. & Purich, D. L. (1978) J. Biol. Chem. 253, 4683-4687). Hence, it is clear from Fig. 2a that although glibenclamide affects the rate of polymerization there is not a strong influence on the extent of polymerization.
EXAMPLE 3 : Taxol inhibits, and nocodazole stimulates, sulfonylurea effects on insulin secretion
Taxol, a promotor of microtubule polymerization, and nocodazole, which induces microtubule depolymerization, have earlier been shown to inhibit glucose-stimulated insulin secretion from isolated rat islets of Langerhans (Howell, S.L. et al. (1982)
Bioscience Reports 2, 795-801). Taxol and nodocazole were used to study the functional importance of β-cell microtubules during the process of insulin secretion.
The basal medium used for isolation and for conducting the experiments was a buffer containing 125 mM NaCl; 5.9 mM KC1; 1.3 mM CaCl2; 1.2 mM MgCl2; and 25 mM HEPES (pH 7.4). BSA was added to the medium at the concentration of 1 mg/ml. The dynamics of insulin release were studied by perifusing β-cell aggregates mixed with Bio- Gel P4 polyacrylamide beads (BioRad, Richmond, CA), in a 0.5 ml column at 37°C (Kanatsuna, T. et al. (1981) Diabetes 30, 231-234). The flow rate was 0.2 ml/min. Two- min fractions were collected and insulin content was analyzed by radioimmunoassay.
Cells were incubated with 5 μM nocodazole for 30 min or 25 μM taxol for 15 min prior to starting perifusion of the cells. Taxol was present during the whole experiment. The control cells were incubated with their respective vehicle solutions. Protocols were initiated at the times indicated in Fig. 3 with either 1 μM glibenclamide or 15 mM glucose. The data represent the mean ± SEM of four experiments.
Incubation with 5 μM nocodazole and 25 μM Taxol did not affect the basal level of insulin secretion nor did they induce visible changes in the microtubule organization, and the architecture of the β-cells remained intact (Fig. 3a). In the presence of non-stimulating (3 mM) as well as stimulating (15 mM) concentrations of glucose, the presence of 25 μM of Taxol prevented the increase in insulin secretion elicited by 1 μM glibenclamide (Fig. 3b). In contrast, under the same experimental conditions (3 and 15 mM glucose) but in the presence of 5 μM nocodazole, 1 μM glibenclamide induced a 5 -fold increase in insulin secretion (at 3 mM glucose) and a one-fold increase at 15 mM glucose (Fig. 3c).
These results suggest that a dynamic microtubule system is required for sulfonylureas to stimulate secretion of insulin. Moreover, they suggest that microtubule dynamics are probably essential for the traffic of insulin containing granules. When taxol, which inhibits tubulin turnover, is present the microtubules are "locked" in place and no more transport can occur. Nocodazole, on the other hand, disrupts microtubules and as such may promote tubulin turnover/treadmilling. This may promote the transport of insulin containing granules to the point of secretion. EXAMPLE 4: Characterization of the 65 kDa polypeptide
Several strategies are employed to determine the identity of the ~65kDa polypeptide that binds sulfonylureas. Firstly, after sulfonylurea binding to pancreatic β-cell (intact or isolated cytosol) the proteins are separated with 2-dimensional gel electrophoresis. The spot representing the 65 kDa polypeptide binding to glibenclamide is excised and subjected to MALDI analysis.
Additionally, after in vitro binding of sulfonylureas to β-cell cytosol, samples are separated by HPLC and fractions containing the radiolabeled protein separated on SDS-PAGE, and subject to gel staining and autoradiography. The radioactive band will be excised from the gel and sequenced.

Claims

1. An isolated mammalian polypeptide characterized by binding to glibenclamide and an apparent molecular mass of approximately 65 kDa.
2. An isolated mammalian polypeptide according to claim 1, characterized by an apparent molecular mass of approximately 65 kDa when the cytosolic fraction of pancreatic β- cells from ob/ob mice is analyzed by SDS-PAGE.
3. A method for the identification of a compound capable of binding to the polypeptide according to claim 1 or 2, comprising the steps
(a) contacting the said polypeptide with a test compound; and
(b) determining whether the said test compound binds to the said polypeptide.
4. The method according to claim 3, comprising the steps
(a) contacting the said polypeptide with (i) a test compound and (ii) a reference compound binding to said polypeptide; and
(b) determining the binding of the said test compound, relative to that of the said reference compound, to the said polypeptide.
5. The method according to claim 3 or 4 for identification of a compound capable of stimulating insulin secretion, wherein binding of the said test compound to the said polypeptide is indicative of a compound capable of stimulating insulin secretion.
6. The method according to claim 4 or 5 wherein the said reference compound is a sulfonylurea compound, or a derivative thereof.
7. A method for the identification of a compound capable of binding to tubulin, comprising the steps (a) contacting tubulin with (i) a test compound and (ii) a reference compound which is a sulfonylurea compound, or a derivative thereof, binding to tubulin; and (b) determining the binding of the said test compound, relative to that of the said reference compound, to tubulin.
8. The method according to claim 7 for identification of a compound capable of stimulating insulin secretion, wherein binding of the said test compound to tubulin is indicative of a compound capable of stimulating insulin secretion.
9. A method for the identification of a compound capable of binding to tubulin, comprising the steps (a) contacting tubulin with (i) a test compound and (ii) a reference compound which is a sulfonylurea compound, or a derivative thereof, binding to tubulin binding to tubulin; and
(b) determining the stimulating effect of the said test compound, relative to that of the said reference compound, to polymerization or turnover of tubulin.
10. The method according to claim 9 for identification of a compound capable of stimulating insulin secretion, wherein a stimulating effect on polymerization or turnover of tubulin is indicative of a compound capable of stimulating insulin secretion.
11. The method according to any one of claims 3 to 10 wherein the said reference compound is a sulfonylurea compound.
12. The method according to any one of claim 11 wherein the said sulfonylurea compound is glibenclamide.
13. The method according to any one of claims 3 to 12 wherein the said tubulin is β- tubulin
14. The method according to any one of claims 3 to 13 wherein the said tubulin derived from a human source.
15. Use of a compound identified by the method according to any one of claims 3 to 14 in the manufacture of a medicament for the treatment of diabetes and/or hyperglycemia.
16. A method for the treatment of diabetes and/or hyperglycemia comprising administering to a patient in need thereof an effective amount of a compound identified by the method according to any one of claims 3 to 14.
17. Use of a sulfonylurea compound, or a derivative thereof, in the identification of an active agent binding to tubulin, or stimulating polymerization and/or turnover of tubulin, said active agent being useful for stimulating insulin secretion.
1 . Use of a sulfonylurea compound, or a derivative thereof, in the identification of an active agent binding to the polypeptide as defined in claim 1 or 2, said active agent being useful for stimulating insulin secretion.
19. The use according to claim 17 or 18 wherein the said sulfonylurea compound is glibenclamide.
20. The use according to any one of claims 17 to 19 wherein the said active agent is a sulfonylurea compound or a derivative thereof.
21. The use according to any one of claims 17 to 20 wherein the said active agent is stimulating insulin secretion independently of sulfonylurea receptor activity.
22. The use according to any one of claims 17 to 21 wherein the said active agent is stimulating insulin secretion in the presence, but not in the absence, of stimulatory glucose concentrations.
PCT/SE2000/001563 1999-08-13 2000-08-10 Methods for identification of compounds stimulating insulin secretion WO2001013121A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2001517172A JP2003507365A (en) 1999-08-13 2000-08-10 Methods for identifying compounds that promote insulin secretion
CA002380983A CA2380983A1 (en) 1999-08-13 2000-08-10 Methods for identification of compounds stimulating insulin secretion
EP00953612A EP1200835A1 (en) 1999-08-13 2000-08-10 Methods for identification of compounds stimulating insulin secretion
NZ516788A NZ516788A (en) 1999-08-13 2000-08-10 Methods for identification of compounds stimulating insulin secretion
AU66032/00A AU6603200A (en) 1999-08-13 2000-08-10 Methods for identification of compounds stimulating insulin secretion
NO20020576A NO20020576D0 (en) 1999-08-13 2002-02-05 Methods for identifying compounds that stimulate insulin secretion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902918-3 1999-08-13
SE9902918A SE9902918D0 (en) 1999-08-13 1999-08-13 Methods for identification of compounds stimulating insulin secretion

Publications (1)

Publication Number Publication Date
WO2001013121A1 true WO2001013121A1 (en) 2001-02-22

Family

ID=20416679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2000/001563 WO2001013121A1 (en) 1999-08-13 2000-08-10 Methods for identification of compounds stimulating insulin secretion

Country Status (8)

Country Link
EP (1) EP1200835A1 (en)
JP (1) JP2003507365A (en)
AU (1) AU6603200A (en)
CA (1) CA2380983A1 (en)
NO (1) NO20020576D0 (en)
NZ (1) NZ516788A (en)
SE (1) SE9902918D0 (en)
WO (1) WO2001013121A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003148A1 (en) * 1990-08-14 1992-03-05 Amylin Corporation Improved hypoglycemics
WO1996011398A1 (en) * 1994-10-07 1996-04-18 Merck & Co., Inc. Process for assessing tubulin protein polymerization
WO1999003477A1 (en) * 1997-07-18 1999-01-28 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003148A1 (en) * 1990-08-14 1992-03-05 Amylin Corporation Improved hypoglycemics
WO1996011398A1 (en) * 1994-10-07 1996-04-18 Merck & Co., Inc. Process for assessing tubulin protein polymerization
WO1999003477A1 (en) * 1997-07-18 1999-01-28 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1191, no. 2, 1994, pages 278 - 290 *
DANIEL G. PIPELEERS ET AL.: "Regulation of tubulin synthesis in islets of Langerhans", PROC. NATL. ACAD. SCI. USA, vol. 73, no. 9, 1976, pages 3188 - 3191, XP002954089 *
DATABASE BIOSIS [online] KRAMER WERNER ET AL.: "Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor: II. Photoaffinity labeling of a 65 kDa protein by (3H)glimepiride", XP002954031, retrieved from 09324075 accession no. Dialog Information Services, File 5 Database accession no. 199497332445 *
DATABASE MEDLINE [online] BRAUN M. ET AL.: "Evidence for a 65 kDa sulfonylurea receptor in rat pancreatic zymogen granule membrane", XP002954029, retrieved from 09234757 accession no. Dialog Information Services, File 155 Database accession no. 97415417 *
DATABASE MEDLINE [online] LUZI L. ET AL.: "Glibenclamide: An old drug with a novel mechanism of action?", XP002954032, retrieved from 09424751 accession no. Dialog Information Services, File 155 Database accession no. 98113425 *
DATABASE MEDLINE [online] OZANNE S.E. ET AL.: "Intracellular localization and molecular heterogenity of the sulphonylurea receptor in insulin-secreting cells", XP002954030, retrieved from 08299002 accession no. Dialog Information Services, File 155 Database accession no. 95278655 *
DIABETOLOGIA, vol. 38, no. 3, March 1995 (1995-03-01), (GERMANY), pages 277 - 282 *
E.F. PFEIFFER, ULM ET AL.: "Biochemistry and biophysics of the pancreatic B-cell. Microtubule Interactions in Islets of Langerhans", HORMONIC AND METABOLIC RESEARCH, vol. 10, 1980, pages 163 - 167, XP001104826 *
FEBS LETTERS, vol. 411, no. 2-3, 14 July 1997 (1997-07-14), (NETHERLANDS), pages 255 - 259 *
W.J. MALAISSE ET AL.: "The stimulus-secretion coupling of glucose-induced insulin release VIII. Combined effects of glucose and sulfonylureas", EUROP. J. CLIN. INVEST., vol. 2, 1972, pages 85 - 90, XP002954071 *

Also Published As

Publication number Publication date
JP2003507365A (en) 2003-02-25
AU6603200A (en) 2001-03-13
NO20020576L (en) 2002-02-05
EP1200835A1 (en) 2002-05-02
NZ516788A (en) 2003-07-25
NO20020576D0 (en) 2002-02-05
SE9902918D0 (en) 1999-08-13
CA2380983A1 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
Danial et al. Dual role of proapoptotic BAD in insulin secretion and beta cell survival
Abriel et al. Defective regulation of the epithelial Na+ channel by Nedd4 in Liddle's syndrome
Zhang et al. Fibrillogenic amylin evokes islet β-cell apoptosis through linked activation of a caspase cascade and JNK1
Dusek et al. The differentiation-dependent desmosomal cadherin desmoglein 1 is a novel caspase-3 target that regulates apoptosis in keratinocytes
Höltje et al. The neuronal monoamine transporter VMAT2 is regulated by the trimeric GTPase Go2
Feng et al. Polo-like kinase interacts with proteasomes and regulates their activity
US20070059684A1 (en) Method of identifying an antiviral agent
Kizhakkedath et al. Endoplasmic reticulum quality control of LDLR variants associated with familial hypercholesterolemia
Borrello et al. NUPR1 interacts with eIF2α and is required for resolution of the ER stress response in pancreatic tissue
Corsi et al. Alteration of α‐spectrin ubiquitination due to age‐dependent changes in the erythrocyte membrane
US6586188B1 (en) Method for identification of compounds that bind to β-tubulin and stimulate insulin secretion
KR20010082559A (en) A method of modulating the efficiency of translation termination and degradation of aberrant mRNA involving a surveillance complex comprising human Upf1p, eucaryotic release factor 1 and eucaryotic release factor 3
WO2001013121A1 (en) Methods for identification of compounds stimulating insulin secretion
WO1997012617A9 (en) Proteins involved in targeting of peptidyl transfer center, and corresponding therapeutic agents and methods
JP2003527068A (en) Angiostatin receptor
US20080050755A1 (en) Method for screening for chemotherapeutic treatments for cancer
Cochrane Leptin signaling in pancreatic β-cells: a mechanism to regulate KATP channel trafficking and β-cell electrical activity
KR20040002970A (en) Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
KR101404332B1 (en) Screening method for the agents for treating insulin-related diseases by monitoring KATP channel trafficking
Tarapore Phosphorylation dependent regulation of GLI transcription factors and Hedgehog signaling
Capera Aragonés Functional implications of Kv1. 3 spatial organization
US7846683B2 (en) Method for identifying agents which modulate cell growth or survival
CA2380507A1 (en) Compositions and methods to enhance sensitivity of cancer cells to mitotic stress
Soekmadji et al. Secretory control: Evidence for agonist regulation of post-fusion vesicle behaviour
Murfitt Dysregulation of Mitofusin-2 in the diabetic heart

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000953612

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2380983

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 516788

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 66032/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000953612

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 516788

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 516788

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000953612

Country of ref document: EP